For Healthcare Professionals

A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

clipboard-pencil

About the study

The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease or metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on CT/MRI for prostate cancer and have at least 1 lesion accessible for biopsy. For Part 2B participants with HCC, intermediate disease is allowed.
  2. Eastern Cooperative Oncology Group Performance Status of 0 or 1
  3. Must have received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to tumor type, if such a therapy exists
  4. Prior anti-cancer treatments such as chemotherapy, radiotherapy, or hormonal are permitted for some participants
  5. Willing and able to comply with all study procedures

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Primary central nervous system (CNS) malignancies, tumors with CNS metastases as the only site of disease or active brain metastases will be excluded
  2. Other active malignancy requiring concurrent intervention
  3. Prior organ allograft
  4. Active, known, or suspected autoimmune disease

Other protocol-defined inclusion/exclusion criteria apply


pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Advanced Cancer

Age (in years)

18+

Phase

Phase 1/Phase 2

Participants needed

425

Est. Completion Date

Sep 19, 2024

Treatment type

Interventional


Sponsor

Bristol-Myers Squibb

ClinicalTrials.gov identifier

NCT03369223

Study number

CA030001

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.